Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.68% | 21.29% | 17.64% | 23.44% | 18.93% |
| Total Depreciation and Amortization | -7.47% | -3.94% | 0.67% | 1.21% | 0.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.53% | -27.92% | -0.95% | -8.35% | -11.18% |
| Change in Net Operating Assets | 16.66% | -22.06% | -594.76% | -314.02% | -209.80% |
| Cash from Operations | 13.07% | 15.75% | 11.71% | 4.00% | -3.69% |
| Capital Expenditure | -60.53% | 54.22% | 79.58% | 93.79% | 88.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.07% | -53.65% | -40.16% | -37.38% | -70.31% |
| Cash from Investing | -17.60% | -53.65% | -39.34% | -36.49% | -69.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 29.04% | 19.54% | 13.83% | 21.70% | 3,234.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 34.93% | 21.92% | 16.22% | 24.17% | 3,234.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.42% | -137.35% | -252.32% | -72.91% | -331.70% |